HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...
Because CRISPR news tends to focus on the applications of genome editing—such as treating genetic diseases or improving food—it may be easy to forget that the system is, at its core, used by bacteria ...
After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications Promega ...
Daily Maverick on MSN
Remembering Nelson Mandela’s meeting with antiviral pioneer and Nobel laureate David Baltimore
David Baltimore explained to Mr Mandela, in a language so precise as only he could, that there was no vaccine for Aids and ...
Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback